Intravitreal infliximab for choroidal neovascularization in patients refractory to conventional treatments

International Journal of Immunopathology and Pharmacology

Volumn 26, Issue 3, 2013, Pages 765-768

  Semeraro, F ^a   Romano, Mario R ^b,c   Danzi, P ^a   Angi, M ^a   Costagliola, C ^c  

^a UNIVERSITY OF BRESCIA   (Italy)

^b Scuola di Medicina e Istituto Clinico Humanitas   (Italy)

^c UNIVERSITY OF MOLISE   (Italy)

Author keywords

Age related macular degeneration; Bevacizumab; Central retina venous occlusion; Choroid neovascularization; Infliximab; Retinal angiomatous proliferation

Indexed keywords

ATROPINE; BEVACIZUMAB; INFLIXIMAB; STEROID; VERTEPORFIN;

AGED; ARTICLE; CASE REPORT; CENTRAL RETINA VEIN OCCLUSION; CLINICAL FEATURE; DRUG EFFICACY; DRUG SAFETY; EXUDATIVE MACULAR DEGENERATION; FEMALE; HUMAN; MALE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA ANGIOGRAPHY; RETINA ANGIOMATOUS PROLIFERATION; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; RETINAL THICKNESS; SLIT LAMP; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UVEITIS; VISUAL ACUITY; VITRECTOMY;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; COMPASSIONATE USE TRIALS; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; PROSPECTIVE STUDIES; RETINA; RETINAL VEIN OCCLUSION; STEROIDS; TIME FACTORS; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY; VITRECTOMY; VON HIPPEL-LINDAU DISEASE;

EID: 84887444390     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201302600321     Document Type: Article

References (7)

1. Hosseini H, Safaei A, Khalili MR, et al. Intravitreal infliximab in experimental endotoxin-induced uveitis. Eur J Ophthalmol 2009; 19:818-23.
2. Prendiville C, O'Doherty M, Moriarty P, Cassidy L. The use of infliximab in ocular inflammation. Br J Ophthalmol 2008; 92:823-25. (Pubitemid 351839577)
3. Theodossiadis PG, Liarakos VS, Sfikakis PP, Vergados IA, Theodossiadis GP. Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration. Am J Ophthalmol 2009; 147:825-30.
4. Arias L, Caminal JM, Badia MB, Rubio MJ, Catala J, Pujol O. Intravitreal infliximab in patients with macular degeneration who are nonresponders to antivascular endothelial growth factor therapy. Retina 2010; 30:1601-8.
5. Giganti M, Beer PM, Lemanski N, Hartman C, Schartman J, Falk N. Adverse events after intravitreal infliximab (Remicade). Retina 2010; 30:71-80.
6. Pulido JS, Pulido JE, Michet CJ, Vile RG. More questions than answers: a call for a moratorium on the use of intravitreal infliximab outside of a well-designed trial. Retina 2010; 30:1-5.
7. Zeltser R, Valle L, Tanck C, Holyst MM, Ritchlin C, Gaspari AA. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein. Arch Dermatol 2001; 137:893-99. (Pubitemid 32641648)